Finding the target after screening the phenotype.

Although most screening for new drug leads is being directed at known or emerging molecular targets, there has been a renaissance in screening based on changes in cell or organismal phenotypes. Phenotype-based screening is accompanied by the challenge of identifying the molecular target or targets bound by the drug leads and responsible for their pharmacological activity. A variety of technologies and approaches are being explored for target identification after phenotypic screening. Direct approaches employing affinity chromatography, expression cloning and protein microarrays analyze the compound bound to its target. Indirect approaches are based on comparison of the genome-wide activity profile of the compound with databases of the activity profiles of other compounds with known targets or activity profiles following specific genetic changes. This review will use case studies of target identification efforts and highlight the advantages and disadvantages of the various approaches to target identification after phenotypic screening.

[1]  Sunkyu Kim,et al.  Proteomics-based Target Identification , 2003, Journal of Biological Chemistry.

[2]  R Scott Lokey,et al.  Forward chemical genetics: progress and obstacles on the path to a new pharmacopoeia. , 2003, Current opinion in chemical biology.

[3]  E J Licitra,et al.  A three-hybrid system for detecting small ligand-protein receptor interactions. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[4]  B. Kreider,et al.  Drug receptor identification from multiple tissues using cellular-derived mRNA display libraries. , 2002, Chemistry & biology.

[5]  P. Brown,et al.  Drug target validation and identification of secondary drug target effects using DNA microarrays , 1998, Nature Medicine.

[6]  Paul A Clemons,et al.  Chemical genomic profiling of biological networks using graph theory and combinations of small molecule perturbations. , 2003, Journal of the American Chemical Society.

[7]  W. Dower,et al.  An in vitro polysome display system for identifying ligands from very large peptide libraries. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Grant W. Brown,et al.  Integration of chemical-genetic and genetic interaction data links bioactive compounds to cellular target pathways , 2004, Nature Biotechnology.

[9]  J. Heitman,et al.  Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast , 1991, Science.

[10]  A. Coulson,et al.  A functional genomic analysis of cell morphology using RNA interference , 2003, Journal of biology.

[11]  J Bruce German,et al.  Metabolomics and biochemical profiling in drug discovery and development. , 2002, Current opinion in molecular therapeutics.

[12]  J. C. Hinshaw,et al.  Discovering Modes of Action for Therapeutic Compounds Using a Genome-Wide Screen of Yeast Heterozygotes , 2004, Cell.

[13]  A. Tanaka.  [A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[14]  Paul A Clemons,et al.  Complex phenotypic assays in high-throughput screening. , 2004, Current opinion in chemical biology.

[15]  D. Botstein,et al.  A gene expression database for the molecular pharmacology of cancer , 2000, Nature Genetics.

[16]  S. Horinouchi,et al.  Radicicol Binds and Inhibits Mammalian ATP Citrate Lyase* , 2000, The Journal of Biological Chemistry.

[17]  L. Neckers,et al.  Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Yeon Gyu Yu,et al.  Identification of hNopp140 as a binding partner for doxorubicin with a phage display cloning method. , 2002, Chemistry & biology.

[19]  S. Savinov,et al.  The cloning of human genes using cDNA phage display and small-molecule chemical probes. , 2001, Combinatorial chemistry & high throughput screening.

[20]  M. Kirschner,et al.  A chemical inhibitor of N-WASP reveals a new mechanism for targeting protein interactions , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[21]  N. Kley,et al.  Chemical dimerizers and three-hybrid systems: scanning the proteome for targets of organic small molecules. , 2004, Chemistry & biology.

[22]  Minoru Yoshida,et al.  [Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A]. , 1990, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[23]  J. Rothberg,et al.  The characterization of PPAR alpha ligand drug action in an in vivo model by comprehensive differential gene expression profiling. , 2001, Functional & integrative genomics.

[24]  S. Schreiber,et al.  Printing proteins as microarrays for high-throughput function determination. , 2000, Science.

[25]  Michael I. Jordan,et al.  Chemogenomic profiling: identifying the functional interactions of small molecules in yeast. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[26]  M. Snyder,et al.  Recent developments in analytical and functional protein microarrays. , 2003, Current opinion in molecular therapeutics.

[27]  D. Julius,et al.  The capsaicin receptor: a heat-activated ion channel in the pain pathway , 1997, Nature.

[28]  Tae-Wook Kang,et al.  Facilitated forward chemical genetics using a tagged triazine library and zebrafish embryo screening. , 2003, Journal of the American Chemical Society.

[29]  S. Tunaru,et al.  PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect , 2003, Nature Medicine.

[30]  Ronald W. Davis,et al.  Functional profiling of the Saccharomyces cerevisiae genome , 2002, Nature.

[31]  S. Haggarty,et al.  Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. , 1999, Science.

[32]  H. Hidaka,et al.  Isolation of cDNAs encoding cellular drug-binding proteins using a novel expression cloning procedure: drug-western. , 1999, Molecular pharmacology.

[33]  Timothy J Mitchison,et al.  Small molecules, big impact: a history of chemical inhibitors and the cytoskeleton. , 2002, Chemistry & biology.

[34]  Y. Kawazoe,et al.  [Synthetic small molecules that control stem cell fate]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[35]  S. Schreiber,et al.  A receptor for the immuno-suppressant FK506 is a cis–trans peptidyl-prolyl isomerase , 1989, Nature.

[36]  J. Rothberg,et al.  The characterization of PPARα ligand drug action in an in vivo model by comprehensive differential gene expression profiling , 2001, Functional & Integrative Genomics.

[37]  Xiaofeng S Zheng,et al.  Genetic and genomic approaches to identify and study the targets of bioactive small molecules. , 2004, Chemistry & biology.

[38]  V. Cornish,et al.  An optimized dexamethasone-methotrexate yeast 3-hybrid system for high-throughput screening of small molecule-protein interactions. , 2003, Analytical biochemistry.

[39]  Anne E Carpenter,et al.  Systematic genome-wide screens of gene function , 2004, Nature Reviews Genetics.

[40]  Makoto Kinoshita,et al.  [Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[41]  C. Nguyên,et al.  Chemogenomic identification of Ref-1/AP-1 as a therapeutic target for asthma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Lani F. Wu,et al.  Multidimensional Drug Profiling By Automated Microscopy , 2004, Science.

[43]  Oksana Sirenko,et al.  Method for analyzing signaling networks in complex cellular systems. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Sebastian Meier-Ewert,et al.  A three-hybrid approach to scanning the proteome for targets of small molecule kinase inhibitors. , 2004, Chemistry & biology.

[45]  J. Bruce German,et al.  Lipid metabolome-wide effects of the PPARγ agonist rosiglitazones⃞s The online version of this article (available at http://www.jlr.org) contains an additional 4 tables. Published, JLR Papers in Press, August 16, 2002. DOI 10.1194/jlr.M200169-JLR200 , 2002, Journal of Lipid Research.

[46]  P. Schultz,et al.  Identification of a novel protein regulating microtubule stability through a chemical approach. , 2004, Chemistry & biology.

[47]  Leslie J. Browne,et al.  Chemogenomics – pharmacology with genomics tools , 2002 .

[48]  D. Austin,et al.  Display cloning: functional identification of natural product receptors using cDNA-phage display. , 1999, Chemistry & biology.

[49]  D. Sabatini,et al.  Microarrays of cells expressing defined cDNAs , 2001, Nature.

[50]  W. Bornmann,et al.  The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[51]  J Mottram,et al.  Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors. , 2000, Chemistry & biology.

[52]  E. Berg,et al.  An integrative biology approach for analysis of drug action in models of human vascular inflammation , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[53]  E. Jacoby,et al.  Chemogenomics: an emerging strategy for rapid target and drug discovery , 2004, Nature Reviews Genetics.

[54]  C. Conrad,et al.  Automatic identification of subcellular phenotypes on human cell arrays. , 2004, Genome research.

[55]  C. Crews,et al.  Eponemycin exerts its antitumor effect through the inhibition of proteasome function. , 1999, Cancer research.

[56]  H. Handa,et al.  High-performance affinity beads for identifying drug receptors , 2000, Nature Biotechnology.